Int J Cardiol. 2010 Jun 11;141(3):320-2. Epub 2009 Jan 12.

High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.

Fukutomi T, Takeda Y, Suzuki S, Ito T, Joh T, Itoh M.

Abstract

Although a low level of high density lipoprotein-cholesterol (HDL-C) is an important risk factor for coronary heart disease, few available agents are capable of significantly increasing HDL-C. This multicenter study demonstrated that administration of pitavastatin, a new HMG-CoA reductase inhibitor, significantly and persistently increased HDL-C (from 36.0+/-5.9 to 40.5+/-9.1 mg/dL: p<0.001) and apolipoprotein A-I levels (from 108.4+/-18.0 to 118.7+/-19.3 mg/dL: p<0.01) in 43 hypercholesterolemic patients with low HDL-C over the course of 12 months of treatment. This suggests that pitavastatin may contribute to reduction in coronary heart disease.

PMID:: 19138801; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. [Clin Ther. 2008]
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, et al. Clin Ther. 2008 Jun; 30(6):1089-101.
Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. [J Atheroscler Thromb. 2009]
Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia.
Teramoto T, Shimano H, Yokote K, Urashima M. J Atheroscler Thromb. 2009 Oct; 16(5):654-61.
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. [Clin Ther. 2007]
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, et al. Clin Ther. 2007 Nov; 29(11):2365-73.
Review Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. [Clin Cardiol. 2003]
Review Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, Maccubbin DL, Mercuri M. Clin Cardiol. 2003 Nov; 26(11):509-14.
Review Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. [Drugs. 2004]
Review Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M, Roberts A, Davies S, Rees A. Drugs. 2004; 64(11):1181-96.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

High density lipoprotein cholesterol and apolipoprotein A-I are persistently ele...
High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.
Int J Cardiol. 2010 Jun 11 ;141(3):320-2. Epub 2009 Jan 12 .

PubMed
POMT2 intragenic deletions and splicing abnormalities causing congenital muscula...
POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation.
Eur J Med Genet. 2009 Jul-Aug ;52(4):201-6. Epub 2008 Dec 27 .

PubMed
Bcl-2 family proteins as regulators of oxidative stress.
Bcl-2 family proteins as regulators of oxidative stress.
Semin Cancer Biol. 2009 Feb ;19(1):42-9. Epub 2008 Dec 24 .

PubMed
The physical state of fibronectin matrix differentially regulates morphogenetic ...
The physical state of fibronectin matrix differentially regulates morphogenetic movements in vivo.
Dev Biol. 2009 Mar 15 ;327(2):386-98. Epub 2008 Dec 30 .

PubMed
Protein complexes: the evolution of symmetry.
Protein complexes: the evolution of symmetry.
Curr Biol. 2009 Jan 13 ;19(1):R25-6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information